'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Divis Laboratories has increased 12.24% to Rs 2585 crore. Operating profit margin has jumped from 31.74% to 34.24%, leading to 21.07% rise in operating profit to Rs 885.00 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 38.96% to 36.73%. Employee cost increased from 12.89% to 13.81%. Other expenses fell from 16.18% to 14.56%.
Other income rose 8.86% to Rs 86 crore. PBIDT rose 19.88% to Rs 971 crore. Provision for interest remained nil. Loan funds rose to Rs 4.00 crore as of 31 March 2025 from Rs 3.00 crore as of 31 March 2024. Inventories rose to Rs 3,236.00 crore as of 31 March 2025 from Rs 3,184.00 crore as of 31 March 2024. Sundry debtors were higher at Rs 2,731.0...
Pleaselogin & subscribe to view the full report.
More Reports
-
(26-Feb-2026)
Foseco India
Net down 35% on higher EO Exp
-
(26-Feb-2026)
KSB
Net up 11%, sales up 8%
-
(26-Feb-2026)
Sanofi India
OP down 23.67%
-
(25-Feb-2026)
Schaeffler India
Revenue jumps 28% and profit spurts 36% in Q4CY25
|
|